Your browser doesn't support javascript.
Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
Assawakosri, Suvichada; Kanokudom, Sitthichai; Suntronwong, Nungruthai; Auphimai, Chompoonut; Nilyanimit, Pornjarim; Vichaiwattana, Preeyaporn; Thongmee, Thanunrat; Duangchinda, Thaneeya; Chantima, Warangkana; Pakchotanon, Pattarakul; Srimuan, Donchida; Thatsanatorn, Thaksaporn; Klinfueng, Sirapa; Yorsaeng, Ritthideach; Sudhinaraset, Natthinee; Wanlapakorn, Nasamon; Mongkolsapaya, Juthathip; Honsawek, Sittisak; Poovorawan, Yong.
  • Assawakosri S; Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Kanokudom S; Osteoarthritis and Musculoskeleton Research Unit, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
  • Suntronwong N; Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Auphimai C; Osteoarthritis and Musculoskeleton Research Unit, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
  • Nilyanimit P; Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Vichaiwattana P; Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Thongmee T; Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Duangchinda T; Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Chantima W; Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Pakchotanon P; Molecular Biology of Dengue and Flaviviruses Research Team, National Center for Genetic Engineering and Biotechnology, National Science and Development Agency, National Science and Technology Development Agency, Pathum Thani, Thailand.
  • Srimuan D; Division of Dengue Hemorrhagic Fever Research, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Thatsanatorn T; Siriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Klinfueng S; Molecular Biology of Dengue and Flaviviruses Research Team, National Center for Genetic Engineering and Biotechnology, National Science and Development Agency, National Science and Technology Development Agency, Pathum Thani, Thailand.
  • Yorsaeng R; Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Sudhinaraset N; Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Wanlapakorn N; Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Mongkolsapaya J; Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Honsawek S; Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Poovorawan Y; Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
J Infect Dis ; 226(8): 1372-1381, 2022 10 17.
Article in English | MEDLINE | ID: covidwho-1735587
ABSTRACT

BACKGROUND:

The use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) against SARS-CoV-2 is implemented worldwide. However, waning immunity and breakthrough infections have been observed. Therefore, we hypothesized that the heterologous booster might improve the protection against the delta and omicron variants.

METHODS:

A total of 224 individuals who completed the 2-dose CoronaVac for 6 months were included. We studied reactogenicity and immunogenicity after a heterologous booster with the inactivated vaccine (BBIBP), the viral vector vaccine (AZD1222), and the messenger ribonucleic acid (mRNA) vaccine (both BNT162B2 and mRNA-1273). We also determined immunogenicity at 3- and 6-month boosting intervals.

RESULTS:

The solicited adverse events were mild to moderate and well tolerated. Total receptor binding domain (RBD) immunoglobulin (Ig), anti-RBD IgG, focus reduction neutralization test (FRNT50) against delta and omicron variants, and T-cell response were highest in the mRNA-1273 group followed by the BNT162b2, AZD1222, and BBIBP groups, respectively. We also witnessed a higher total Ig anti-RBD in the long-interval than in the short-interval group.

CONCLUSIONS:

All 4 booster vaccines significantly increased binding and neutralizing antibodies in individuals immunized with 2 doses of CoronaVac. The present evidence may benefit vaccine strategies to thwart variants of concern, including the omicron variant.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Humans Language: English Journal: J Infect Dis Year: 2022 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Humans Language: English Journal: J Infect Dis Year: 2022 Document Type: Article Affiliation country: Infdis